A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism
For patients with AF and/or VTE, we observed that bleeding was highest with rivaroxaban, followed by warfarin, and then apixaban. Rates of thrombosis were higher with apixaban than with warfarin, largely driven by "other" thrombotic events.
Authors
- Suman L. Sood
- Geoffrey D. Barnes (ORCID: https://orcid.org/0000-0002-6532-8440)
- Mona A. Ali (ORCID: https://orcid.org/0000-0003-2416-6702)
- Xiaowen Kong (ORCID: https://orcid.org/0000-0003-4548-3600)
- Jordan K. Schaefer (ORCID: https://orcid.org/0000-0002-7166-386X)
- James B. Froehlich (ORCID: https://orcid.org/0000-0003-2327-8235)
- Scott S. Kaatz (ORCID: https://orcid.org/0000-0002-3080-3328)
- Naina Chipalkatti
- Gregory D Krol
- Brian Haymart
- Josh Errickson
Institutions
- University of Michigan (US)
- Henry Ford Hospital (US)
- Michigan Medicine (US)
- Beaumont Hospital, Royal Oak (US)
- Beaumont Hospital, Troy (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1016/j.jacadv.2025.101714
- Citations
- 3
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- Blue Cross Blue Shield of Michigan Foundation